Payment overview · 2025
General Payments
$229.25
11 reported records · 6 companies
Healthcare provider profile · identity verified
Peter Gibbs Kramer, DO
Allopathic & Osteopathic Physicians|Family Medicine · WILMINGTON, NC · NPI 1285771931
Verified facts
What the public records show
CMS Open Payments records show Peter Gibbs Kramer, DO received $229.25 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.44 | 32.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.52 | 24.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.31 | 13.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$29.42 | 12.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.33 | 9.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.23 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.25 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $75.44 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $59.98 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.31 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $29.42 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 71 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 563 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 381 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 361 | 99 |
| Losartan Potassium | Losartan Potassium | 350 | 106 |
| Lisinopril | Lisinopril | 307 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 67 |
| Omeprazole | Omeprazole | 204 | 62 |
| Simvastatin | Simvastatin | 196 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 54 |
| Gabapentin | Gabapentin | 161 | 41 |
| Alprazolam | Alprazolam | 158 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 54 |
| Clonazepam | Clonazepam | 151 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 48 |
| Prednisone | Prednisone | 136 | 91 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 44 |
| Ozempic | Semaglutide | 116 | 22 |
| Synthroid | Levothyroxine Sodium | 113 | 23 |
| Trazodone Hcl | Trazodone Hcl | 110 | 30 |
| Metformin Hcl Er | Metformin Hcl | 102 | 28 |
| Metformin Hcl | Metformin Hcl | 101 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 34 |
| Bupropion Xl | Bupropion Hcl | 96 | 25 |
| Furosemide | Furosemide | 91 | 29 |
| Ezetimibe | Ezetimibe | 86 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 32 |
| Donepezil Hcl | Donepezil Hcl | 73 | 18 |
| Allopurinol | Allopurinol | 71 | 19 |
| Eliquis | Apixaban | 71 | 16 |
| Farxiga | Dapagliflozin Propanediol | 65 | 17 |
| Mounjaro | Tirzepatide | 63 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 18 |
| Meloxicam | Meloxicam | 59 | 21 |
| Potassium Chloride | Potassium Chloride | 59 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | 13 |
| Montelukast Sodium | Montelukast Sodium | 55 | 14 |
| Celecoxib | Celecoxib | 54 | 16 |
| Sertraline Hcl | Sertraline Hcl | 54 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 13 |
| Atenolol | Atenolol | 50 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 49 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 17 |
| Diazepam | Diazepam | 47 | 11 |
| Ondansetron Odt | Ondansetron | 46 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Carvedilol | Carvedilol | 43 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 43 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 12 |
| Jardiance | Empagliflozin | 41 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 13 |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 16 |
| Ramipril | Ramipril | 34 | suppressed |
| Valsartan | Valsartan | 34 | 11 |
| Amoxicillin | Amoxicillin | 32 | 28 |
| Lorazepam | Lorazepam | 32 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Estradiol | Estradiol | 31 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Azithromycin | Azithromycin | 27 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 15 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Spironolactone | Spironolactone | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.25 · 11 records | PFIZER INC. | AIRSUPRA, AREXVY, BREZTRI, ELIQUIS, FARXIGA, INCEPTIV, Korlym, NURTEC ODT, SHINGRIX, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error